Clinical Trial: IIIb Trial for RC28-E Injection in Participants With DME and wAMD

U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07936487) titled 'IIIb Trial for RC28-E Injection in Participants With DME and wAMD' on Nov. 08.

Brief Summary: The purpose of this study is to primarily determine the safety profile of RC28-E in participants with DME and wAMD. Also explore the efficacy.

Study Start Date: Oct. 30

Study Type: INTERVENTIONAL

Condition: Diabetic Macular Edema (DME) wAMD

Intervention: BIOLOGICAL: RC28-E

Ophthalmic solution for intravitreal injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: RemeGen Co., Ltd.

Published by HT Digital Content Services with permission from Health Daily Digest....